Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients

Table 1 Grade 3/4 side effects in active regimens for advanced gastric cancer

	FAMTX	ECF	EOX	CF	DCF	S1	CS
Anemia	10	8.0-13.1	8.6	26	18	4.0-12.8	26
Thrombocytopenia	8	4.0-4.7	5.2	13	8	0.0-1.3	5
Neutropenia	58	36.0-41.7	27.6	57	82	5.6-11.0	40
Febrile neutropenia	20	8.0-9.3	7.8	12	29	0.0-1.0	3
Diarrhea	7	2.6-6.0	11.9	8	19	3.0-7.7	4
Stomatitis		1.3	2.2	27	21	0.0	1
Hand-foot syndrome	1	3.0-4.3	3.1			0.0	0
Nausea and vomitting	5	10.2-17.0	11.4	17	14	1.0-5.6	11 and 4
Peripheral neuropathy		0.4	4.4	3	8	2.0	0
Lethargy		16.6	24.9	14	19	2.0-5.1	4
Alopecia1	42	44.2-56.0	28.8
Increased creatinine	3	1.0				0.0	0
Ref.	[8]	[8,9]	[9]	[12]	[12]	[16,17]	[16]

¹Alopecia is grade 2 according to CTCAE ver2. FAMTX: 5-FU/Adriamycin/Methotrexate; ECF: Epirubicin/cisplatin/5-FU; EOX: Epirubicin/Oxaliplatin/Capecitabine; CF: Cisplatin/5-FU; DCF: Docetaxel/cisplatin/5-FU; CS: S-1/Cisplatin.